Today: 30 June 2026
Browse Category

NASDAQ:SNDK 29 January 2026 - 9 February 2026

SanDisk stock drops 11% after $750–$1,000 targets pile up on AI memory demand

SanDisk stock drops 11% after $750–$1,000 targets pile up on AI memory demand

SanDisk Corp shares dropped roughly 11% Wednesday morning, erasing part of a recent sharp rally that had sparked a surge of bullish analyst recommendations. The stock slipped 11.2% to $617.88. The swing is crucial because investors view SanDisk as a pure play on AI-driven demand for NAND flash—the storage memory powering phones, PCs, and growing in data centres. Shares surged over 16% Monday following the company’s positive update, with brokers pushing price targets up since.
4 February 2026
·
Sandisk stock jumps as AI storage squeeze drives big forecast and a longer supply deal

Sandisk stock jumps as AI storage squeeze drives big forecast and a longer supply deal

New York, January 30, 2026, 10:06 EST — Regular session Shares of Sandisk jumped roughly 17% to $631.93 on Friday after the flash-storage company raised its quarterly guidance beyond Wall Street’s forecasts. The firm also announced it extended a crucial supply deal with partner Kioxia through 2034. Sandisk projected fiscal third-quarter revenue hitting a midpoint of $4.6 billion, with adjusted earnings per share at $14—far exceeding analysts’ estimates of $2.77 billion in revenue and $4.37 EPS, per LSEG data. CEO David Goeckeler summed it up: “Customers prefer supply over price.”
30 January 2026
···
1 2 3 4 5 … 9

Stock Market Today

  • Telix Pharmaceuticals (ASX:TLX) tops Australian growth stocks with large insider holdings
    June 30, 2026, 3:11 AM EDT. Telix Pharmaceuticals (ASX:TLX) is at the front of Australian growth stocks with high insider ownership, seen as a sign of management confidence. The biopharma group, focused on radiopharmaceuticals in cancer imaging and care, pulled in about US$803.8 million in sales, most of that coming from the U.S. The company's market cap stands at A$5.5 billion. Telix's cancer pipeline is broad, and its commercial footing is firm. Its key products, Illuccix and Gozellix, support 2026 revenue targets of US$950-970 million. There's still risk from regulatory and pricing pressure, but insiders remain aligned, and partnerships with United Imaging and Regeneron support the growth story. Also mentioned: Lindian Resources (ASX:LIN), market cap A$1.7 billion, which is pushing ahead on a rare earths project in Malawi. Both names show that shareholder interest tracks with insider backing.
Go toTop